17-AAG | Enzo Life Sciences BML-EI308-0001 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

17-AAG

catalog :

BML-EI308-0001

quantity :

1 mg

citations: 10

Reference
Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang H, et al. Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J Clin Exp Med. 2015;8:6687-701 pubmed
Kim H, Lee S, Um J, Kim M, Hyun S, Gong E, et al. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci. 2015;11:923-34 pubmed publisher
Choi I, Lee Y, Park J, Song Y, Chang E, Kang S. Radicicol induces intracellular accumulation of glycan-deficient clusterin variant. Biochem Biophys Res Commun. 2015;458:555-560 pubmed publisher
Chen P, Chang J, Li L, Tsai H, Shen M, Lin P. Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells. Mol Pharmacol. 2013;83:605-12 pubmed publisher
Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter Landsberg C. 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy. PLoS ONE. 2010;5:e8753 pubmed publisher
Banerji U, Sain N, Sharp S, Valenti M, Asad Y, Ruddle R, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008;62:769-78 pubmed publisher
Johnson A, Wagner A, Cheney C, Smith L, Lucas D, Guster S, et al. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2007;139:837-44 pubmed
Williams C, Tabios R, Linehan W, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol. 2007;178:1528-32 pubmed
Meyer P, Roychowdhury S, Kini A, Alkan S. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells. Leuk Res. 2008;32:143-9 pubmed
Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007;1113:202-16 pubmed

product information

Product ID :

BML-EI308

Catalog Number :

BML-EI308-0001

Product Name :

17-AAG

Product Type :

Biochemical

Size :

1 mg

list of Pubmed id :

26221207, 26157347, 25680466, 23229511, 20090920, 18193424, 17949452, 17707057, 17617451, 17513464

Product Description :

17-AAG is a less toxic and more stable analog of geldanamycin. It is an HSP90 inhibitor that displays a 100-fold higher affinity for HSP90 derived from tumor cells compared to HSP90 from normal cells. 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol, cisplatin, and UCN-014. 17-AAG causes the inactivation, destabilization and eventual degradation of HIF-1α. Inhibitor of telomerase activity. Inducer of apoptosis with antitumor activity. Inducer of macroautophagy.

ALTnames :

17-(Allylamino)-17-desmethoxygeldanamycin

Purity :

≥98% (TLC)

Storage :

-20°C